BioPharmSignal logoBioPharmSignal

Biotech News

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

Seres Therapeutics (MCRB)Seres TherapeuticsCompany update

Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and

Related news

MCRBSeres Therapeutics2026-07-08 11:00 EST

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

MCRBSeres Therapeutics2026-11-04 12:00 EST

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

View all latest news

Seres Therapeutics

Live Biotherapeutic Platform Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science. SER-155 SER-155 is...

Recent company news

MCRBSeres Therapeutics2026-11-04 12:00 EST

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

MCRBSeres Therapeutics2026-11-03 12:00 EST

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

MCRBSeres Therapeutics2026-10-15 11:00 EST

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

MCRBSeres Therapeutics2026-09-08 22:00 EST

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MCRBSeres Therapeutics2026-09-01 11:00 EST

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close
2.09 USD
Market cap
70.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States